ArticleCell reports2018
Glycosylation of Human IgA Directly Inhibits Influenza A and Other Sialic-Acid-Binding Viruses.
Article in Cell reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 84 citations in OpenAlex.
- N-glycopedia: libraries for native N-glycan structural analysis.Nature communications · 2026Article
- Structural promiscuity in the human circulatory IgA1 clonal repertoire.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Multimerization of secretory IgA enhances antiviral activity by aggregating influenza A virus particles.Communications biology · 2026Article
- Immunoglobulin G N-glycosylation remodeling in viral infections: immunomodulatory roles and potential biomarker implications.Frontiers in immunology · 2026Review
- Glycan Structures of Human Immunoglobulins and Their Roles.Advances in experimental medicine and biology · 2026Review
- Dietary xylooligosaccharides modulate oxidative stress and pathogen resistance in growing rabbits.Journal of animal science and biotechnology · 2025Article
- N-Glycosylation of Antibodies: Biological Effects During Infections and Therapeutic Applications.Antibodies (Basel, Switzerland) · 2025Review
- IgA displays site- and subclass-specific glycoform differences despite equal glycoenzyme expression.Cell communication and signaling : CCS · 2025Article
- Immunoglobulin A carries sulfated andFrontiers in molecular biosciences · 2025Article
- AsymmetricJournal of the American Chemical Society · 2024Article
- Compartment-specific antibody correlates of protection to SARS-CoV-2 Omicron in macaques.iScience · 2024Article
- Bacterial Community Influences the Effects ofAnimals : an open access journal from MDPI · 2024Article
- Beta-spike-containing boosters induce robust and functional antibody responses to SARS-CoV-2 in macaques primed with distinct vaccines.Cell reports · 2023Article
- Engineered Secretory Immunoglobulin A provides insights on antibody-based effector mechanisms targetingbioRxiv : the preprint server for biology · 2023Article
- Review
- Gender dimorphism in IgA subclasses in T2-high asthma.Clinical and experimental medicine · 2023Article
- Article
- Salivary IgA as a Surrogate Biomarker for Microbial Infections in Postoperative Patients Receiving Chemo-Radio-Therapy for Head and Neck Cancer.Journal of laboratory physicians · 2023Article
- A nasal vaccine with inactivated whole-virion elicits protective mucosal immunity against SARS-CoV-2 in mice.Frontiers in immunology · 2023Article
- The IgA of hares (Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoglobulin A (IgA) plays an important role in protecting our mucosal surfaces from viral infection, in maintaining a balance with the commensal bacterial flora, and in extending maternal immunity via breast feeding. Here, we report an additional innate immune effector function of human IgA molecules in that we demonstrate that the C-terminal tail unique to IgA molecules interferes with cell-surface attachment of influenza A and other enveloped viruses that use sialic acid as a receptor. This antiviral activity is mediated by sialic acid found in the complex N-linked glycans at position 459. Antiviral activity was observed even in the absence of classical antibody binding via the antigen binding sites. Our data, therefore, show that the C-terminal tail of IgA subtypes provides an innate line of defense against viruses that use sialic acid as a receptor and the role of neuraminidases present on these virions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.